Watson Announces Approval of Novel Oral Contraceptive

Loading...
Loading...
Watson Pharmaceuticals
WPI
today announced the U.S. Food and Drug Administration approval of a novel oral contraceptive product – the first and only low dose oral contraceptive to combine 0.8 mg norethindrone and 0.025 mg ethinyl estradiol in chewable form, with four 75 mg ferrous fumarate placebo tablets. Taken orally, once daily, the product is proven effective in lowering the risk of pregnancy.
Posted In: NewsFDAHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...